Marvell Technology CDR (CAD Hedged)

Ladies and gentlemen, thank you for standing by. My name is Brent and I will be your conference operator today. At this time, I would like to welcome everyone to the Moravo Healthcare Q3 2021 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question at that time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press star one. At this time, I would like to turn today's call over to Mr. Jesse Ledger, President and Chief Executive Officer. Please go ahead, sir.

Great. Thanks, Brent. Good morning, everyone. Thank you for joining our call today. On the call with me this morning from Moravo is Mary Jane Burkett, Moravo's Vice President and Chief Financial Officer. and Tina Lucades, Miravo's Vice President, Secretary, and General Counsel. This morning's call makes reference to a presentation on our website that should be viewed concurrently. If you have not downloaded this presentation, I would invite you to do so now by visiting miravohealthcare.com and scrolling down to the bottom of the page. You can then click on the link. Before we begin, I'd like to remind everyone that some of the statements made during the presentation may be considered forward-looking. and the company cautions investors that results of future operations may differ from those anticipated. We ask you to review the cautionary statements and other information contained in the company's filing on CDAR, including the company's Q3 financial statements and MD&A that was filed today, as well as the company's annual information form for fiscal 2020, which identifies certain factors that could cause actual results to differ materially from those projected and any forward-looking statements made during the meetings. Copies of the annual information form and other filings are of course available online. The Moravo business boasts a diversified commercial product portfolio of over 20 products. We're continuing to see organic growth of our key promoted brands through market share expansion and have also recently launched or anticipate launching in the near future new products both in Canada and international markets. Our existing business has a proven track record and is well positioned for continued growth. Our financial results year to date and our strong cash position demonstrate the resiliency of our business in the face of the COVID-19 pandemic. Despite these challenges posed by the evolving COVID-19 pandemic, our diverse business remains well positioned for growth and we continue to pay down our debt on a quarterly basis. Our commercial business segment continues to grow organically through the efforts of our commercial sales and marketing team. This business segment contributed $11.2 million, or 66% of total revenue for the third quarter of 2021. Our three key promoted products, Blexitin, Cambia, and Souvex, continued to demonstrate year-over-year prescription growth and generated $8.1 million in revenue for Q3. Overall, our commercial segment represents 65% of our total revenue year-to-date in 2021. All of our promotional efforts remain focused on Blexton, Cambia, Suvex, and Neobisc. However, the remaining mature products in our commercial segment, highlighted on the next slide, continue to contribute in a meaningful way to our bottom line. These mature products have either lost market exclusivity to generic competitors or are not in our therapeutic core focus areas. During the quarter, the revenue in our licensing and royalty segment was $3.3 million, or 20% of our total revenue. Royalty revenue is generated from licensing of our intellectual property and related products globally under exclusive licensing agreements to our partners. Our royalty revenue has been negatively impacted by continued reductions in net sales of BOMOPO in the United States as a result of generic competition, which entered the market in 2020, as well as a decline in the company's results royalty due to the social impact of the COVID-19 pandemic. We do anticipate the global results business to regain strength as the world continues to slowly reopen from the COVID-19 pandemic. We do see continued growth potential for our licensing and royalty business as we remain focused on identifying new international partnering opportunities for our products in this segment. The production and services segment revenue for the third quarter was $2.4 million, or 14% of our total revenue. The sources of revenue in this segment are from products manufactured by our facility in Varennes, Quebec, or from product contract manufactured from Mirabeau and supplied to our distribution partners. I will now turn the call over to Mary Jane, who will take you through our financial results for the third quarter of 2021 and year to date.

Thanks, Jesse. Today's presentation includes reference to certain measures that do not have a standardized meaning under IFRS. These measures include adjusted total revenue, adjusted EBITDA, and cash value of loans. Morava believes that shareholders, investment analysts, and other readers find such measures helpful in understanding Morava's financial performance and the company's outstanding loans. For a description of how Morava defines these non-IFRS financial measures, as well as the reconciliation of these measures, please refer to slide 26 and 28 of the presentation, which is posted on the Morava website, as well as Morava's management's discussion and analysis filed on CDAR. During the third quarter of 2021, the company recorded a $14.7 million non-cash impairment of goodwill and intangible assets in the commercial business and licensing and royalty segments, as it has changed commercial expectations for certain products in response to COVID-19 trends. Additional details regarding the company's methodology and assumptions are disclosed in Note 4 and Note 5 of the unaudited condensed consolidated interim financial statements. and discussed in the company's MD&A. For your reference, slides five through eight outline the products and related revenue streams that comprise each of the company's business segments, which are referenced throughout the presentation. Adjusted total revenue was $17.1 million and $51.6 million for the three and nine months ended September 30, 2021, compared to $16.7 million and 53.6 million for the three and nine months ended September 30th, 2020. The 0.4 million increase in adjusted total revenue in the current quarter was primarily due to an increase of 1.8 million in the commercial business segment and an increase of 0.4 million of revenue from the licensing and royalty business segment, offset by a decrease of 1.8 million of revenue from the production and service business segment. Revenue for the commercial business segment increased during the three months ended September 30th, 2021, due to a $1.8 million increase in sales of the company's promoted products, Blackton, Cambia, Suvex, and Mioba. In the current quarter, revenue from the company's mature products was consistent with the three months ended September 30th, 2020. The production and service business segment revenues decreased during the three months ended September 30th, 2021, primarily due to a decrease in Pensee 2% product sales, which was slightly offset by an increase in sales of Penn State to the company's European partner. The increase in revenue in the licensing royalty business segments during the three months ended September 30th, 2021, was primarily due to a 0.5 million increase in royalty earned on the European net sales of Immobo, and a 0.2 million increase in royalty earned from net sales of Ysbrala, and a 0.2 million increase from the recognition of milestones in the SUBEX-related SK Chemicals contract. The increase in license revenue in the current three-month period was slightly offset by an unfavorable foreign exchange movement where the stronger Canadian dollar against the US dollar reduced the contribution from US-denominated royalty streams, as well as a 0.6 million decrease in the royalty earned on US net sales of Immobo due to a competitor launching a generic version of Immobo in the US in March 2020. The company earned a $0.2 million and $1 million royalty on U.S. net sales of Immobo during the three and nine months ended September 30, 2021, compared to a $0.8 million and $4.4 million during the three and nine months ended September 30, 2020. Adjusted EBITDA was $7 million for the three months ended September 30, 2021, compared to $6.6 million for the comparative quarter. During the current quarter, a 2.3 million increase in gross profit contribution from the company's commercial business segment net a 0.4 million decrease in inventory step-up expense, and a 0.3 million increase in gross profit from the company's licensed and royalty business segment was offset by a 1.2 million decrease in gross profit contribution from the company's production and service business segment, a 0.8 million increase in sales and marketing expenses, and a 0.2 million increase in general and administrative expenses. During the current quarter, the company did not record government assistance from the Canadian emergency wage subsidy, compared to $1.1 million in the comparative three-month period. Adjusted EBITDA was $18.8 million for the nine months ended September 30, 2021, compared to $22.2 million for the comparative nine-month period. During the nine months ended September 30, 2021, a $4.3 million increase in gross profit from the company's commercial business segment net a $1 million decrease in inventory step-up expense, was more than offset by a $5 million decrease in contribution from the company's licensed and royalty business segment, and a $1 million decrease in gross profit contribution from the production and service business segment, a $1.4 million increase in sales and marketing expenses, and a $0.2 million increase in general and administrative expenses, net a $0.1 million increase in stock-based compensation. During the three and nine months ended September 30th, 2021, the company repaid US $2.9 million and US $8.3 million of the amortization loan to Deerfield, reducing its cash value of loans outstanding to US $90.9 million. Since the inception of the Deerfield financing on December 31st, 2018, the company has repaid US $27.6 million towards the Deerfield loans, The interest rate for both the amortization loan and convertible loan is a fixed 3.5%. The company anticipates making a U.S. $2.5 million payment to Deerfield over the next week. As at November 10th, the company had 11.4 million shares outstanding. Attached to the company's amortization loan are 25.6 million warrants issued to Deerfield at a $3.53 Canadian strike price. of which 11.3 million are currently classified as flexible exercise shares. The company's convertible loan, which may be converted into common shares with the company at year-field option, at a U.S. $2.70 per share conversion, Moravo shares closed at $1.60 per share on November 10th. The company's amortization and convertible loans mature and outstanding warrants expire on December 31st, 2024. As at September 30th, 2021, the company had cash on hand of $28.4 million with an enterprise value of $103.8 million. Jesse will now continue with our business update.